A Phase 3 clinical trial involving triptorelin was listed as recruiting as of September 2, 2026. The trial, registered as NCT05879926, is titled "Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25."
The study is designed to evaluate whether adding adjuvant chemotherapy to ovarian function suppression plus endocrine therapy provides benefit in premenopausal patients with this specific breast cancer profile. Triptorelin is used in the trial in the context of ovarian function suppression, according to the trial listing.
The trial is currently in Phase 3 and its status is listed as recruiting. No results have been posted for this trial as of the date reported. The trial record does not include efficacy or safety outcomes at this stage of recruitment.
This update reflects the trial's registration status only. No conclusions about the therapeutic approach can be drawn until the trial reports further data. Readers interested in the broader clinical and regulatory context for triptorelin can consult the compound overview for additional background.